Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Knapp, Martin
1997.
Costs of schizophrenia.
British Journal of Psychiatry,
Vol. 171,
Issue. 6,
p.
509.
Slaveska, Karmen
Hollis, Chris
and
Bramble, David
1998.
Use of antipsychotics by child and adolescent psychiatrists.
Psychiatric Bulletin,
Vol. 22,
Issue. 11,
p.
685.
Cookson, Ronald F
and
Huybrechts, Krista F
1998.
Risperidone: An assessment of its economic benefits in the treatment of schizophrenia.
Journal of Medical Economics,
Vol. 1,
Issue. 1-4,
p.
103.
Knapp, MRJ
1998.
Measuring the economic benefit of treatment with atypical antipsychotics.
European Psychiatry,
Vol. 13,
Issue. S1,
p.
37s.
Knapp, MRJ
1998.
Measuring the economic benefit of treatment with atypical antipsychotics.
European Psychiatry,
Vol. 13,
Issue. ,
p.
37s.
Edwards, Jane
Maude, Dana
McGorry, Patrick D.
Harrigan, Susan M.
and
Cocks, John T.
1998.
Prolonged recovery in first-episode psychosis.
British Journal of Psychiatry,
Vol. 172,
Issue. S33,
p.
107.
Lecompte, Damien
and
Cookson, Ron F
1999.
The economic value of atypical antipsychotics: A comparison of risperidone and olanzapine revisited.
International Journal of Psychiatry in Clinical Practice,
Vol. 3,
Issue. 1,
p.
3.
Lecomte, Pascal
De Hert, Marc
van Dijk, Marc
Nuijten, Mark
Nuyts, Guy
and
Persson, Ulf
2000.
A 1-Year Cost-Effectiveness Model for the Treatment of Chronic Schizophrenia with Acute Exacerbations in Belgium.
Value in Health,
Vol. 3,
Issue. 1,
p.
1.
Pandarakalam, James Paul
2000.
Atypical neuroleptics.
Hospital Medicine,
Vol. 61,
Issue. 1,
p.
10.
Kerwin, R. W.
2001.
The role of atypical antipsychotic drugs in schizophrenia.
Psychiatric Bulletin,
Vol. 25,
Issue. 8,
p.
281.
Kuperberg, Gina
Kerwin, Robert
and
Murray, Robin
2002.
Developments in the pharmacological treatment of schizophrenia.
Expert Opinion on Investigational Drugs,
Vol. 11,
Issue. 10,
p.
1335.
eLetters
No eLetters have been published for this article.